Trial Profile
An Open-label Phase 1b Study of ARQ 092 in Combination With Other Antineoplastic Agents in Subjects With Selected Solid Tumors
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 14 Dec 2023
Price :
$35
*
At a glance
- Drugs Anastrozole (Primary) ; Carboplatin (Primary) ; Miransertib (Primary) ; Paclitaxel (Primary)
- Indications Endometrial cancer; Ovarian cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors ArQule
- 28 Sep 2020 Status changed to discontinued.
- 17 Jul 2020 Status changed from active, no longer recruiting to completed.
- 07 May 2019 Status changed from recruiting to active, no longer recruiting.